AstraZeneca reports publication of Fasenra Phase 2 trial results in NEJM
A Phase 2 trial has demonstrated that Fasenra can achieve near-complete depletion of eosinophils and improve clinical outcomes in hypereosinophilic syndrome, AstraZeneca announced. The results are published in the New England Journal of Medicine. In the randomized phase of the 20-patient trial, the primary efficacy endpoint was the percentage of patients who reduced their absolute blood eosinophil counts by 50% or more at week 12. This was achieved by 90% of patients treated with Fasenra compared with 30% of patients treated with placebo, a statistically significant difference. In the open-label phase of the trial, 74% of patients maintained a reduction in eosinophil counts and had clinical improvements in their symptoms through week 48. Of these patients, 64% were able to taper background HES medications. In patients from whom tissue biopsies were obtained, there was near-complete depletion of eosinophils following treatment with Fasenra.